que tu évolus positivement
même si ça ne peut sans doute pas être linéaire
même si ça ne peut sans doute pas être linéaire
September 24, 2026 at 8:02 PM
que tu évolus positivement
même si ça ne peut sans doute pas être linéaire
même si ça ne peut sans doute pas être linéaire
A new AI review! evolus/pencil ⭐2.5/5.0
Pencil is a long-running open-source UI prototyping and wireframing tool with a sizable user base and broad platform support via Electron.
https://gitrated.com/evolus/pencil
Pencil is a long-running open-source UI prototyping and wireframing tool with a sizable user base and broad platform support via Electron.
https://gitrated.com/evolus/pencil
March 29, 2026 at 5:40 AM
A new AI review! evolus/pencil ⭐2.5/5.0
Pencil is a long-running open-source UI prototyping and wireframing tool with a sizable user base and broad platform support via Electron.
https://gitrated.com/evolus/pencil
Pencil is a long-running open-source UI prototyping and wireframing tool with a sizable user base and broad platform support via Electron.
https://gitrated.com/evolus/pencil
“Drop the f-word,” David Moatazedi, Evolus president and CEO, declared in an Instagram Reel. Instead, he recommended providers call it “hyaluronic acid gel.”
America Fell in Love With Filler. Then Came the Great Deflate
Filler sales have been declining in the U.S. Is this the end of Instagram Face?
www.wsj.com
September 6, 2026 at 2:42 PM
“Drop the f-word,” David Moatazedi, Evolus president and CEO, declared in an Instagram Reel. Instead, he recommended providers call it “hyaluronic acid gel.”
Just published my writeup on $700m US small cap Evolus, disrupting the injectable market! Tariff concerns eased as pharmaceuticals are exempt. High-risk/high-reward, but on verge of profitability. Check it out: elevatorpitch.substack.com/p/evolus?r=3... #Evolus #smallcap
🇺🇸 🦋Evolus: Injecting Profitability
A disruptor in injectables with a visible path to +30% revenue growth p.a. and cash profitability
elevatorpitch.substack.com
April 3, 2025 at 1:05 PM
Just published my writeup on $700m US small cap Evolus, disrupting the injectable market! Tariff concerns eased as pharmaceuticals are exempt. High-risk/high-reward, but on verge of profitability. Check it out: elevatorpitch.substack.com/p/evolus?r=3... #Evolus #smallcap
Life’s busy, and you need treatments that work! We feel you. To learn more about Jeuveau® and the other products we offer, call us and book your appointment today.
#jeuveau #evolus #performancebeauty #evolvewithus #frownlines #injectables
#jeuveau #evolus #performancebeauty #evolvewithus #frownlines #injectables
April 17, 2025 at 12:05 AM
Life’s busy, and you need treatments that work! We feel you. To learn more about Jeuveau® and the other products we offer, call us and book your appointment today.
#jeuveau #evolus #performancebeauty #evolvewithus #frownlines #injectables
#jeuveau #evolus #performancebeauty #evolvewithus #frownlines #injectables
Evolus Sees Toxin Market Stabilizing, Evolysse Gaining Traction, Raises 2028 Revenue Targets at Conference
March 15, 2026 at 11:48 PM
Evolus Sees Toxin Market Stabilizing, Evolysse Gaining Traction, Raises 2028 Revenue Targets at Conference
🚀 New Remote Job Alert!
💼 Multi-Channel Manager - Berlin, Germany
🏢 Evolus
🌍 EU
📁 Customer Service
💰 €60,000 - €90,000
#RemoteJobs #RemoteWork #WorkFromHome #Hiring #JobOpportunity
Apply now: https://remote-work.app/job/evolus-multi-channel-manager-berlin-germany
💼 Multi-Channel Manager - Berlin, Germany
🏢 Evolus
🌍 EU
📁 Customer Service
💰 €60,000 - €90,000
#RemoteJobs #RemoteWork #WorkFromHome #Hiring #JobOpportunity
Apply now: https://remote-work.app/job/evolus-multi-channel-manager-berlin-germany
November 10, 2025 at 8:15 AM
🚀 New Remote Job Alert!
💼 Multi-Channel Manager - Berlin, Germany
🏢 Evolus
🌍 EU
📁 Customer Service
💰 €60,000 - €90,000
#RemoteJobs #RemoteWork #WorkFromHome #Hiring #JobOpportunity
Apply now: https://remote-work.app/job/evolus-multi-channel-manager-berlin-germany
💼 Multi-Channel Manager - Berlin, Germany
🏢 Evolus
🌍 EU
📁 Customer Service
💰 €60,000 - €90,000
#RemoteJobs #RemoteWork #WorkFromHome #Hiring #JobOpportunity
Apply now: https://remote-work.app/job/evolus-multi-channel-manager-berlin-germany
Galderma $GALD delivered an impressive H1: raised guidance and ex-Nemo margin close to 30%! Still prefer Evolus $EOLS as a pure play, but huge credit to Galderma for driving growth with innovations in a challenging environment.
July 24, 2025 at 5:42 PM
Galderma $GALD delivered an impressive H1: raised guidance and ex-Nemo margin close to 30%! Still prefer Evolus $EOLS as a pure play, but huge credit to Galderma for driving growth with innovations in a challenging environment.
Je sais pas pourquoi tu veux absolument tordre cette info dans ts les sens. Quand tu évolus dans un milieu homophobe et le max que tu peux en dire c'est "tant pis" avec un petit sourire (sa réaction à la question), bah t'es homophobe, c'est tout. Je mute la conversation, tu as les infos utiles.
August 23, 2025 at 1:18 PM
Je sais pas pourquoi tu veux absolument tordre cette info dans ts les sens. Quand tu évolus dans un milieu homophobe et le max que tu peux en dire c'est "tant pis" avec un petit sourire (sa réaction à la question), bah t'es homophobe, c'est tout. Je mute la conversation, tu as les infos utiles.
Evolus trades at 3x gross profit $EOLS
September 13, 2026 at 5:00 AM
Evolus trades at 3x gross profit $EOLS
Evolus is growing revenue at its fastest clip since 2024 $EOLS
September 12, 2026 at 11:15 PM
Evolus is growing revenue at its fastest clip since 2024 $EOLS
Evolus Stock Seen Up 77% by Wall Street
https://insidemedspa.com/article/evolus-stock-analyst-upside/
#medspa #medicalaesthetics
https://insidemedspa.com/article/evolus-stock-analyst-upside/
#medspa #medicalaesthetics
Evolus Stock Seen Up 77% by Wall Street
Analysts project significant upside for the Jeuveau maker, signaling confidence in neuromodulator competition and market share gains.
insidemedspa.com
September 7, 2026 at 12:05 PM
Evolus Stock Seen Up 77% by Wall Street
https://insidemedspa.com/article/evolus-stock-analyst-upside/
#medspa #medicalaesthetics
https://insidemedspa.com/article/evolus-stock-analyst-upside/
#medspa #medicalaesthetics
📄 #EOLS 10-Q — what changed
MD&A now says: "Our current commercial product portfolio includes Jeuveau ® (prabotulinumtoxinA-xvfs) and Evolysse ® , a collection of injectable hyaluronic acid, or HA, gels."
📈 Full redline → https://www.formdelta.com/ticker/EOLS
#10Q #EOLS #StockMarket
MD&A now says: "Our current commercial product portfolio includes Jeuveau ® (prabotulinumtoxinA-xvfs) and Evolysse ® , a collection of injectable hyaluronic acid, or HA, gels."
📈 Full redline → https://www.formdelta.com/ticker/EOLS
#10Q #EOLS #StockMarket
FormDelta — Insider Trading Alerts
What Evolus, Inc. changed in their own words, quarter over quarter.
www.formdelta.com
September 4, 2026 at 11:12 PM
Evolus $EOLS: HC Wainwright & Co. reiterated its Buy rating with a $13.00 price target.
https://fundspec.ai/s/EOLS/analysts
Set a price alert once and let it watch the tape for you.
https://fundspec.ai/s/EOLS/analysts
Set a price alert once and let it watch the tape for you.
August 25, 2026 at 12:15 PM
Evolus $EOLS: HC Wainwright & Co. reiterated its Buy rating with a $13.00 price target.
https://fundspec.ai/s/EOLS/analysts
Set a price alert once and let it watch the tape for you.
https://fundspec.ai/s/EOLS/analysts
Set a price alert once and let it watch the tape for you.
Evolus (NASDAQ:EOLS) Releases Earnings Results, Misses Estimates By $0.08 EPS
Evolus (NASDAQ:EOLS – Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.08), FiscalAI reports. The…
Evolus (NASDAQ:EOLS – Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.08), FiscalAI reports. The…
Evolus (NASDAQ:EOLS) Releases Earnings Results, Misses Estimates By $0.08 EPS
Evolus (NASDAQ:EOLS – Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.08), FiscalAI reports. The company had revenue of $84.08 million during the quarter, compared to the consensus estimate of $81.55 million. Here are the key takeaways from [...]
news-area.com
August 6, 2026 at 3:31 PM
Evolus (NASDAQ:EOLS) Releases Earnings Results, Misses Estimates By $0.08 EPS
Evolus (NASDAQ:EOLS – Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.08), FiscalAI reports. The…
Evolus (NASDAQ:EOLS – Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.08), FiscalAI reports. The…
Evolus (NASDAQ:EOLS) Posts Earnings Results, Misses Expectations By $0.08 EPS
Evolus (NASDAQ:EOLS – Get Free Report) announced its earnings results on Wednesday. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.08), FiscalAI reports.…
Evolus (NASDAQ:EOLS – Get Free Report) announced its earnings results on Wednesday. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.08), FiscalAI reports.…
Evolus (NASDAQ:EOLS) Posts Earnings Results, Misses Expectations By $0.08 EPS
Evolus (NASDAQ:EOLS – Get Free Report) announced its earnings results on Wednesday. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.08), FiscalAI reports. The firm had revenue of $84.08 million for the quarter, compared to analyst estimates of $81.55 million. Here are the key takeaways from [...]
news-area.com
August 6, 2026 at 1:58 PM
Evolus (NASDAQ:EOLS) Posts Earnings Results, Misses Expectations By $0.08 EPS
Evolus (NASDAQ:EOLS – Get Free Report) announced its earnings results on Wednesday. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.08), FiscalAI reports.…
Evolus (NASDAQ:EOLS – Get Free Report) announced its earnings results on Wednesday. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.08), FiscalAI reports.…
#EOLS Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook
https://www.stocktitan.net/news/EOLS/evolus-reports-strong-second-quarter-2026-financial-results-delivers-jcpypzztb08f.html
https://www.stocktitan.net/news/EOLS/evolus-reports-strong-second-quarter-2026-financial-results-delivers-jcpypzztb08f.html
Evolus Expects 2030 U.S. Profhilo Launch, $100M+ Peak Revenue
Adjusted EBITDA reached $4.7 million, while Estyme launched in Europe and expanded to Canada, Australia and New Zealand with expected 2028 commercialization.
www.stocktitan.net
August 5, 2026 at 8:05 PM
#EOLS Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook
https://www.stocktitan.net/news/EOLS/evolus-reports-strong-second-quarter-2026-financial-results-delivers-jcpypzztb08f.html
https://www.stocktitan.net/news/EOLS/evolus-reports-strong-second-quarter-2026-financial-results-delivers-jcpypzztb08f.html
📰 #Finance
"Establishes a complementary injectable hyaluronic acid (HA) gel portfolio alongside Jeuveau® and Nuceiva® across all Evolus commercial markets Further leverages Evolus’ international commercial infrastructure to support long-term profitable growth NEWPORT BEACH, Calif. —…"
"Establishes a complementary injectable hyaluronic acid (HA) gel portfolio alongside Jeuveau® and Nuceiva® across all Evolus commercial markets Further leverages Evolus’ international commercial infrastructure to support long-term profitable growth NEWPORT BEACH, Calif. —…"
Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand
financialpost.com
August 4, 2026 at 1:32 PM
Rice Hall James & Associates LLC Boosts Stock Position in Evolus, Inc. $EOLS
Rice Hall James & Associates LLC increased its holdings in Evolus, Inc. (NASDAQ:EOLS – Free Report) by 8.8% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,254,819…
Rice Hall James & Associates LLC increased its holdings in Evolus, Inc. (NASDAQ:EOLS – Free Report) by 8.8% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,254,819…
Rice Hall James & Associates LLC Boosts Stock Position in Evolus, Inc. $EOLS
Rice Hall James & Associates LLC increased its holdings in Evolus, Inc. (NASDAQ:EOLS – Free Report) by 8.8% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,254,819 shares of the company’s stock after purchasing an additional 101,375 shares during the period. Rice Hall James & [...]
news-area.com
July 26, 2026 at 10:28 PM
Rice Hall James & Associates LLC Boosts Stock Position in Evolus, Inc. $EOLS
Rice Hall James & Associates LLC increased its holdings in Evolus, Inc. (NASDAQ:EOLS – Free Report) by 8.8% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,254,819…
Rice Hall James & Associates LLC increased its holdings in Evolus, Inc. (NASDAQ:EOLS – Free Report) by 8.8% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,254,819…